Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Journal of Medicinal Chemistry
|
October 13, 2006
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists
Brett D Allison, Victor K Phuong, Laura C McAtee, et al.
Oncotarget
|
August 25, 2016
Glutamatergic stimulation induces GluN2B translation by the nitric oxide-Heme-Regulated eIF2α kinase in cortical neurons
Eva Ramos-Fernández, Marta Tajes, Gerard Ill-Raga, et al.
Molecular Pharmacology
|
March 5, 2011
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor
Terrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues
Mark D Rosen, Hariharan Venkatesan, Hillary M Peltier, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 16, 2001
Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases
J G Conway, R C Andrews, B Beaudet, et al.
Combinatorial Chemistry & High Throughput Screening
|
August 17, 2005
Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping
Millard H Lambert, R Kevin Blackburn, Theresa D Seaton, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 22, 2001
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution
D L Musso, M W Andersen, R C Andrews, et al.
Nature Communications
|
June 13, 2024
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Journal of Medicinal Chemistry
|
October 13, 2006
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists
Brett D Allison, Victor K Phuong, Laura C McAtee, et al.
Oncotarget
|
August 25, 2016
Glutamatergic stimulation induces GluN2B translation by the nitric oxide-Heme-Regulated eIF2α kinase in cortical neurons
Eva Ramos-Fernández, Marta Tajes, Gerard Ill-Raga, et al.
Molecular Pharmacology
|
March 5, 2011
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor
Terrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues
Mark D Rosen, Hariharan Venkatesan, Hillary M Peltier, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 16, 2001
Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases
J G Conway, R C Andrews, B Beaudet, et al.
Combinatorial Chemistry & High Throughput Screening
|
August 17, 2005
Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping
Millard H Lambert, R Kevin Blackburn, Theresa D Seaton, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 22, 2001
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution
D L Musso, M W Andersen, R C Andrews, et al.
Nature Communications
|
June 13, 2024
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Sebastijan Hobor, Maise Al Bakir, Crispin T Hiley, et al.
Page
of 5